The stock market is mixed Tuesday, with the Dow Jones Industrial Average up 0.02%, the Nasdaq down 0.54% and the S&P 500 down 0.20%. Today’s winners include a pharmaceutical company entering into a partnership with a competitor to develop a cancer drug and a retailer whose CEO is departing in the near future. Today’s sole loser is a drug company ending a study of a brain cancer drug.
These are Tuesday’s winners and loser.
Biggest Winners
Shares of Galena Biopharma, Inc (NASDAQ: GALE) are up 10.86% to $2.26 on trading volume of 5.4 million shares. The biopharmaceutical company has signed an agreement with Teva Pharmaceutical Industries Limited (NYSE: TEVA) to develop its cancer treatment, NeuVax. The 52-week high is $3.54.
Shares of Big Lots Inc. (NYSE: BIG) are up 7.67% to $30.19 on trading volume of 3.9 million shares. CEO Steve Fishman announced he is retiring in 2013 after eight years as head of the company. The 52-week high is $47.22.
Biggest Loser
Shares of Geron Corporation (NASDAQ: GERN) are down 27.70% to $1.07 on trading volume of 3.7 million shares. The company announced it is ending research on a drug candidate to treat brain cancer, which will result in the layoff of 40 of its 107 full-time staffers. Before Tuesday, the 52-week low was $1.21.
Samuel Weigley
Follow him on Twitter: SWeigley
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
